Real-world data on persons living with HIV (PLWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) while virologically suppressed: 96-week data from the Icona cohort

被引：0

作者：

Monforte, A. d'Arminio ^{[1
]}

Tavelli, A. ^{[1
]}

Cingolani, A. ^{[2
,3
]}

Taramasso, L. ^{[4
]}

Mussini, C. ^{[5
]}

Piconi, S. ^{[6
]}

Calcagno, A. ^{[7
,8
]}

Orofino, G. ^{[9
]}

Cicalini, S. ^{[10
]}

Castagna, A. ^{[11
,12
]}

Ceccherini-Silberstein, F. ^{[13
]}

Gori, A. ^{[14
,15
]}

Guaraldi, G. ^{[5
]}

Antinori, A. ^{[10
]}

机构：

[1] Icona Fdn, Milan, Italy

[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Infect Dis Unit, Rome, Italy

[3] Univ Cattolica Sacro Cuore, Dept Safety & Bioeth, Rome, Italy

[4] Univ Genoa, Osped Policlin San Martino IRCCS, Unit Infect Dis, Genoa, Italy

[5] Univ Modena & Reggio Emilia, AOU Modena, Infect & Trop Dis Unit, Modena, Italy

[6] ASST Lecco, Infect Dis Unit, Lecce, Italy

[7] Osped Amedeo Savoia, Unit Infect Dis, Turin, Italy

[8] Univ Turin, Dept Med Sci, Turin, Italy

[9] ASL Citta Torino, Div A Infect Dis, Osped Amedeo Savoia, Turin, Italy

[10] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Clin Dept HIV, AIDS Unit, Rome, Italy

[11] IRCCS San Raffaele Sci Inst, Infect Dis Unit, Milan, Italy

[12] Univ Vita Salute San Raffaele, Milan, Italy

[13] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy

[14] ASST Fatebenefratelli Sacco, Unit Infect Dis 2, Milan, Italy

[15] Univ Milan, Milan, Italy

来源：

HIV MEDICINE | 2023年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

843

引用

下载

页码：157 / 159

页数：3

共 48 条

[1] Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed: real-world data from the ICONA cohort
Monforte, A. d'Arminio
Tavelli, A.
Cingolani, A.
Taramasso, L.
Mussini, C.
Piconi, S.
Calcagno, A.
Orofino, G.
Cicalini, S.
Castagna, A.
Ceccherini-Silberstein, F.
Gori, A.
Guaraldi, G.
Antinori, A.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 98 - 99
[2] Effectiveness of Bictegravir/ Emtricitabine/Tenofovir Alafenamide(BIC/FTC/ TAF) as switch strategy in virologically suppressed: Real world data from monocentric cohort
Passerotto, R. A.
Lamanna, F.
Farinacci, D.
Dusina, A.
D'Angelillo, A.
Ciccullo, A.
Baldin, G.
Mozzetta, I.
Visconti, E.
Di Giambenedetto, S.
Borghetti, A.
HIV MEDICINE, 2023, 24 : 139 - 140
[3] Real-world experience of bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) in a diverse urban HIV clinic cohort
Doyle, C.
Moriarty, M.
Devitt, E.
HIV MEDICINE, 2020, 21 : 18 - 18
[4] Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BTC/FTC/TAF) in ART-naive patients: real-world data from the ICONA cohort
Tavelli, A.
Marchetti, G.
Vergori, A.
Quiros-Roldan, E.
Malagnino, V.
Vichi, F.
Lichtner, M.
Nozza, S.
Rossotti, R.
Sarmati, L.
Bai, F.
Di Biagio, A.
Antinori, A.
Monforte, A. d'Arminio
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 62 - 63
[5] Weight gain after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in HIV-suppressed patients
Cicalini, S.
Lorenzini, P.
Grilli, E.
Plazzi, M. M.
De Zottis, F.
Camici, M.
Fusto, M.
Gagliardini, R.
Bellagamba, R.
Antinori, A.
HIV MEDICINE, 2021, 22 : 31 - 32
[6] Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort
Monforte, Antonella d'Arminio
Tavelli, Alessandro
Di Biagio, Antonio
Sarmati, Loredana
Marchetti, Giulia C.
Bai, Francesca
Cingolani, Antonella
Roldan, Eugenio Quiros
Mussini, Cristina
Lichtner, Miriam
Vergori, Alessandra
Piconi, Stefania
Orofino, Giancarlo
Fusco, Francesco Maria
Bandera, Alessandra
Nozza, Silvia
Castagna, Antonella
Antinori, Andrea
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (06) : 1279 - 1288
[7] Effectiveness of Bictegravir/ Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) in treatment-experienced people with HIV using real-world data: A systematic review and meta-analysis
Chivite, I.
Berrocal, L.
De lazzari, E.
Navadeh, S.
Lluis, C.
Inciarte, A.
De la Mora, L.
Gonzalez-Cordon, A.
Martinez-Rebollar, M.
Laguno, M.
Torres, B.
Blanco, J. L.
Martinez, E.
Mallolas, J.
Ambrosioni, J.
HIV MEDICINE, 2023, 24 : 70 - 71
[8] Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis
Chivite, Ivan
Berrocal, Leire
de Lazzari, Elisa
Navadeh, Soodabeh
Lluis-Ganella, Carla
Inciarte, Alexy
de la Mora, Lorena
Gonzalez-Cordon, Ana
Martinez-Rebollar, Maria
Laguno, Montserrat
Torres, Berta
Blanco, Jose Luis
Martinez, Esteban
Mallolas, Josep
Ambrosioni, Juan
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (08) : 1775 - 1783
[9] A retrospective, multicentre study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real-world setting in Belgium
Nasreddine, R.
Florence, E.
Yombi, J.
Henrard, S.
Darcis, G.
Van Praet, J.
Vandekerckhove, L.
Allard, S.
Demeester, R.
Messiaen, P.
Ausselet, N.
Delforge, M.
De Wit, S.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 116 - 117
[10] Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
Podzamczer, Daniel
Imaz, Arkaitz
Lopez-Lirola, Ana
Knobel, Hernando
Masia, Mar
Fanciulli, Chiara
Hernandez, Cristina
Lagarde, Maria
Gutierrez, Angela
Curran, Adria
Morano, Luis
Montero-Alonso, Marta
Troya, Jesus
Rigo, Raul
Casadella, Maria
Navarro-Alcaraz, Antonio
Ardila, Fernando
Parera, Mariona
Bernal, Enrique
Echeverria, Patricia
Estrada, Vicente
Hidalgo-Tenorio, Carmen
Macias, Juan
Prieto, Paula
Portilla, Joaquin
Valencia, Eulalia
Vivancos, Maria Jesus
Rivero, Antonio
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (11) : 2696 - 2701

← 1 2 3 4 5 →